Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.50 |
| ▸ | ACHE | P22303 | 6/20 | 0.50 |
| ▸ | CNR1 | P21554 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1593950 | 0.84 | CNR2 (0.56) | CNR2ACHECNR1MAPTSMN1; SMN2 | |
| SCHEMBL1593005 | 0.83 | MAPT (0.51) | CNR2ACHECNR1MAPTSMN1; SMN2 | |
| SCHEMBL1594020 | 0.82 | CNR1 (0.46) | CNR2ACHECNR1MAPTSMN1; SMN2 | |
| SCHEMBL16536339 | 0.82 | PDE1B (0.51) | CNR2CNR1MAPTSMN1; SMN2PDE5A | |
| SCHEMBL29873266 | 0.80 | MAPT (0.45) | CNR2ACHECNR1MAPTSMN1; SMN2 | |
| SCHEMBL29873129 | 0.76 | MAPT (0.46) | CNR2ACHECNR1MAPTSMN1; SMN2 | |
| SCHEMBL23069180 | 0.74 | MAPT (0.50) | CNR2ACHECNR1MAPTSMN1; SMN2 | |
| SCHEMBL1593023 | 0.74 | CNR1 (0.47) | CNR2ACHECNR1MAPTSMN1; SMN2 | |
| SCHEMBL28431878 | 0.74 | CNR1 (0.47) | CNR2CNR1MAPTSMN1; SMN2PDE5A | |
| SCHEMBL24566406 | 0.74 | CNR1 (0.50) | CNR2CNR1MAPTSMN1; SMN2PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394795-B2 | Pyrazole [3, 4-B] pyridine Raf inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2265610-B1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-04-21 | — | — | US | disclosed |
| EP-2265610-A1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111279-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | BRAF, RAF1, ARAF | CNR2 3546/4885ACHE 4879/4885CNR1 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.